NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO

▤ Summary

NeuExcell Therapeutics shared encouraging first-in-human data for NXL-004 in recurrent malignant glioma at ASCO 2026. The study reported a favorable safety profile with no drug-related serious adverse events and common treatment-related effects such as fever and headache. The company also highlighted encouraging efficacy signals, including a median overall survival above 13.2 months and a one-year survival rate of 77.9%. The data support the potential of its in vivo cell conversion platform and AAV-NeuroD1 approach for difficult-to-treat brain tumors.

▦ Linked Companies